| scholarly article | Q13442814 |
| P2093 | author name string | Nobuya Ishii | |
| Shigeo Sato | |||
| Takaaki Miura | |||
| Ryoichi Saitoh | |||
| Toshihiko Fujii | |||
| Yuko Aoki | |||
| Toshikazu Yamazaki | |||
| Naomi Ono | |||
| Atsushi Suda | |||
| Osamu Kondoh | |||
| Takuo Tsukuda | |||
| Yukako Tachibana | |||
| Yoshito Nakanishi | |||
| Kihito Hada | |||
| Toshiyuki Mio | |||
| Kiyoaki Sakata | |||
| Kohnosuke Nakano | |||
| P2860 | cites work | A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells | Q39943622 |
| A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy | Q39960692 | ||
| High HSP90 expression is associated with decreased survival in breast cancer | Q40149432 | ||
| Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin | Q40345142 | ||
| Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins | Q40396742 | ||
| Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. | Q40473008 | ||
| A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors | Q40631570 | ||
| Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin | Q41168181 | ||
| Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 | ||
| The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 | ||
| Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design | Q27672398 | ||
| The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations | Q27851644 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Targeting the dynamic HSP90 complex in cancer | Q28288602 | ||
| Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress | Q28303213 | ||
| HSP90 and the chaperoning of cancer | Q29617504 | ||
| Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study | Q33377626 | ||
| Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer | Q33890758 | ||
| Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy | Q34111364 | ||
| V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors | Q34248395 | ||
| AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity | Q34511038 | ||
| Resiliency and vulnerability in the HER2-HER3 tumorigenic driver | Q34551761 | ||
| Update on Hsp90 inhibitors in clinical trial. | Q35009729 | ||
| Heat shock protein 90 as a molecular target for cancer therapeutics | Q35099516 | ||
| Targeting Hsp90: small-molecule inhibitors and their clinical development | Q37222845 | ||
| Heat shock protein 90 as a drug target: some like it hot. | Q37360814 | ||
| Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. | Q37523202 | ||
| Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation | Q37777749 | ||
| P433 | issue | 2 | |
| P921 | main subject | Erb-b2 receptor tyrosine kinase 2 | Q415271 |
| overexpression | Q61643320 | ||
| P304 | page(s) | 342-349 | |
| P577 | publication date | 2011-12-13 | |
| P1433 | published in | Cancer Science | Q326125 |
| P1476 | title | Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers | |
| P478 | volume | 103 |
| Q34852929 | Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas |
| Q39124519 | Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer |
| Q53091400 | Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. |
| Q38973014 | Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression |
| Q42936269 | Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus |
| Q39287689 | Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor-D. |
| Q39843650 | Regulation of Apoptosis by HER2 in Breast Cancer |
| Q28248791 | Selective targeting of the stress chaperome as a therapeutic strategy |
| Q37466405 | Suppression of inflammatory cascade is implicated in methyl amooranin-mediated inhibition of experimental mammary carcinogenesis |
| Q26765447 | Targeting Cell Survival Proteins for Cancer Cell Death |
| Q36347106 | Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer |
| Q50959754 | The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes |
Search more.